Request more information about Esbriet® (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF)

You are now registering for information that is intended for healthcare professionals

By registering at this site, you certify that you are a healthcare professional licensed in the United States or its territories and are indicating that you wish to receive information about Esbriet, other Genentech products, and related disease education. Genentech's intent is to only provide information to healthcare professionals licensed in the United States or its territories who would likely be treating patients within the FDA-approved indications for this product.

Your contact information (* indicates a required field)


Select
  • Physician
  • Osteopath
  • Physician Assistant
  • Pharmacist
  • Respiratory Therapist
  • Nurse
  • Nurse Practitioner
  • Other

Select
  • Respiratory Care Therapy
  • Radiology
  • Pulmonary Disease
  • Pulmonary Critical Care Medicine
  • Other






By completing and submitting this form, you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents in the future regarding Esbriet, other Genentech products, and related disease education. Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with its Privacy Policy.

Thank you!

You have successfully registered to receive additional information about Esbriet® (pirfenidone)

Be sure to add Esbriet@mail.genentech.com to your address book and allowed senders list to ensure you receive the information you requested.

Note that you can unsubscribe from further communications from Genentech at any time.